Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68

Molecular Cancer Therapeutics

Volumn 8, Issue 1, 2009, Pages 141-151

  Yu, Yong A ^a   Galanis, Charles ^b   Woo, Yanghee ^b   Chen, Nanhai ^a   Zhang, Qian ^a   Fong, Yuman ^b   Szalay, Aladar A ^a,c  

^a GENELUX CORPORATION   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; BIOLOGICAL MARKER; CISPLATIN; GEMCITABINE; GLV 1H68; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER REGRESSION; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFECT; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNE RESPONSE; IN VITRO STUDY; INNATE IMMUNITY; MALE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS CARCINOMA; PRIORITY JOURNAL; SPLENOMEGALY; TUMOR VOLUME; VACCINIA VIRUS; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; CELL LINE, TUMOR; CISPLATIN; DEOXYCYTIDINE; GENE EXPRESSION REGULATION, VIRAL; GENETIC MARKERS; HUMANS; INFLAMMATION; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PANCREATIC NEOPLASMS; VACCINIA; VACCINIA VIRUS; VIRAL PROTEINS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149495955     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0533     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. 2007. CA Cancer J Clin 2007;57:43-66.
2. Fong Y, Gonen M, Rubin D, Radzyner D, Brennan MF. Long-term survival is superior after resection for cancer in high volume centers. Ann Surg 2005;242:540-7.
3. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
4. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10.
5. Woo Y, Adusumilli PS, Fong Y. Advances in oncolytic viral therapy. Curr Opin Investig Drugs 2006;7:549-59.
6. Thorne SH, Hwang TH, Kirn DH. Vaccinia virus and oncolytic virotherapy of cancer. Curr Opin Mol Ther 2005;7:359-65.
7. DiStefano AD, Buzdar AU. Viral-induced remission in chronic lymphocytic leukemia? Arch Intern Med 1979;139:946.
8. Yettra M. Remission of chronic lymphocytic leukemia after smallpox vaccination. Arch Intern Med 1979;139:603.
9. Hansen RM, Libnoch JA. Remission of chronic lymphocytic leukemia after smallpox vaccination. Arch Intern Med 1978;138:1137-8.
10. Mastrangelo MJ, Maguire HC, Jr., Eisenlohr LC, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999;6:409-22.
11. Arakawa S, Jr., Hamami G, Umezu K, Kamidono S, Ishigami J, Arakawa S. Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinoma. Report on two cases. J Cancer Res Clin Oncol 1987;113:95-8.
12. Zhang Q, Yu YA, Timiryasova T, et al. Eradication of solid human tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 2007;67:10038-46.
13. Yu YA, Shabahang S, Timiryasova TM, et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 2004;22:313-20.
14. Yu YA, Szalay AA. A Renilla luciferase-Aequorea GFP (ruc-gfp) fusion gene construct permits real-time detection of promoter activation by exogenously administered mifepristone in vivo. Mol Genet Genomics 2002;268:169-78.
15. Stanziale SF, Petrowsky H, Adusumilli PS, Ben Porat L, Gonen M, Fong Y. Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity. Clin Cancer Res 2004;10:3225-32.
16. Petrowsky H, Roberts GD, Kooby DA, et al. Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J Virol 2001;75:7050-8.
17. Brown SM, MacLean AR, McKie EA, Harland J. The herpes simplex virus virulence factor ICP34.5 and the cellular protein myD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, myD116, and GADD34. J Virol 1997;71:9442-9.
18. Knorr CW, Allen SD, Torres AR, Smee DF. Effects of cidofovir treatment on cytokine induction in murine models of cowpox and vaccinia virus infection. Antiviral Res 2006;72:125-33.
19. Mahalingam S, Farber JM, Karupiah G. The interferon-inducible chemokines MuMig and Crg-2 exhibit antiviral activity in vivo. J Virol 1999;73:1479-91.
20. French AR, Holroyd EB, Yang L, Kim S, Yokoyama WM. IL-18 acts synergistically with IL-15 in stimulating natural killer cell proliferation. Cytokine 2006;35:229-34.
21. Bendrik C, Robertson J, Gauldie J, Dabrosin C. Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo. Cancer Res 2008;68:3405-12.
22. Cao Y, Chen C, Weatherbee JA, Tsang M, Folkman J. gro-β, a -C-X-C-chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice. J Exp Med 1995;182:2069-77.
23. Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-γ inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997;8:207-19.